Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    83
    ...
ATC Name B/G Ingredients Dosage Form Price
L01XX05 UNIDREA G Hydroxycarbamide (or Hydroxyurea) - 500mg 500mg Capsule, hard 2,539,862 L.L
P01BA02 CORVAQUINE G Hydroxychloroquine sulfate - 200mg 200mg Tablet, film coated 1,087,873 L.L
P01BA02 DOLQUINE G Hydroxychloroquine sulfate - 200mg 200mg Tablet, coated 1,191,988 L.L
G03DA03 PROLUTON DEPOT B Hydroxyprogesterone caproate - 250mg/ml 250mg/ml Injectable solution 270,112 L.L
A03BB01 ? HYOSCINE BUTYLBROMIDE G Hyoscine butylbromide - 20mg/ml 20mg/ml Injectable solution 70,392 L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 355,798 L.L
A03BB01 ANTIPAN G Hyoscine N butylbromide - 20mg/ml Injectable solution 2,557,140 L.L
M05BA06 BONAFOR G Ibandronic acid (monosodium monohydrate) - 150mg 150mg Tablet, film coated 383,955 L.L
M05BA06 BONDRONAT B Ibandronic acid (monosodium monohydrate) - 6mg/6ml 6mg/6ml Injectable concentrated powder for solution 24,963,868 L.L
M05BA06 BONVIVA B Ibandronic acid - 150mg 150mg Tablet, film coated 1,265,900 L.L
M05BA06 ADROMUX G Ibandronic acid - 150mg 150mg Tablet, coated 821,088 L.L
M05BA06 BONVIVA B Ibandronic acid - 3mg/3ml 3mg/3ml Injectable solution 3,144,591 L.L
L01EL01 DULLARMA G Ibrutinib - 140mg 140mg Capsule, hard L.L
L01EL01 IMBRUVICA B Ibrutinib - 140mg 140mg Tablet, film coated 187,342,573 L.L
L01EL01 DULLARMA G Ibrutinib - 140mg 140mg Capsule, hard 422,860,803 L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated 562,026,556 L.L
M01AE01 BRUFEN B Ibuprofen - 100mg/5ml 100mg/5ml Syrup 364,181 L.L
M01AE01 CHILDREN'S ADVIL B Ibuprofen - 100mg/5ml 100mg/5ml Suspension 370,901 L.L
M01AE01 CAPTAIN G Ibuprofen - 100mg/5ml 100mg/5ml Suspension 335,321 L.L
M01AE01 FEBRIDEX ELIXIR G Ibuprofen - 100mg/5ml 100mg/5ml Elixir 262,369 L.L
M01AE01 FEVERAL G Ibuprofen - 100mg/5ml 100mg/5ml Suspension 309,724 L.L
M01AE01 IBUSOL G Ibuprofen - 100mg/5ml 100mg/5ml Suspension 309,724 L.L
M01AE01 PEDIAFEN G Ibuprofen - 100mg/5ml 100mg/5ml Suspension 200,936 L.L
M01AE01 PROFINAL G Ibuprofen - 100mg/5ml 100mg/5ml Suspension 208,296 L.L
M01AE01 ADVIL B Ibuprofen - 200mg 200mg Tablet 321,178 L.L
M01AE01 ADVIL LIQUI-GELS B Ibuprofen - 200mg 200mg Capsule 464,970 L.L
M01AE01 CAPTAIN G Ibuprofen - 200mg 200mg Capsule, soft gelatin 383,955 L.L
M01AE51 FLUMIX BENTA G Ibuprofen - 200mg, Guaifenesin - 200mg, Chlorpheniramine maleate - 2mg, Phenylephrine HCl - 5mg Tablet, film coated 875,417 L.L
M01AE51 FLUMIX BENTA G Ibuprofen - 200mg, Guaifenesin - 200mg, Chlorpheniramine maleate - 2mg, Phenylephrine HCl - 5mg Tablet, film coated 460,746 L.L
    ...
    83
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025